LONDON and BOSTON, May 6,
2024 /PRNewswire/ -- Calyx, a leading technology-enabled
provider of Medical Imaging services and IRT/RTSM (Interactive
Response Technology/Randomized Trial Supply Management) today
announced its role in supporting the imaging-based endpoint for the
pivotal trial that supported the FDA's groundbreaking approval of
Iovance Biotherapeutic's AMTAGVI™ (lifileucel). Indicated for
the treatment of adult patients with unresectable or metastatic
melanoma who have relapsed on other front-line therapy, AMTAGVI is
the first cell therapy approved to treat solid tumors, which
account for 90% of all cancers.
Calyx Medical Imaging contributed to the design and
implementation of the imaging components of the accelerated Phase
II clinical trial, enabling 60 investigative sites to capture
patient images via CT, MRI, PET, and skin photography in
compliance with the protocol. Because image review in cell therapy
requires thoughtful and strategic scientific implementation,
Calyx's oncology imaging experts designed an image review
methodology that enabled uniform and consistent evaluation by
Calyx's independent readers.
"The work that Iovance is doing is extremely important, not only
to melanoma patients and their loved ones but also to the broader
oncology research community," said David
Herron, CEO of Calyx Medical Imaging. "We are honored to
have played a role in this important development program and look
forward to continuing our collaboration with the Iovance team."
For more information on Calyx's experience in oncology trial
imaging, visit Oncology Imaging Services| Calyx.
About Calyx
Calyx is a leading global technology-enabled service provider
for Medical Imaging and IRT/RTSM (Interactive Response
Technology/Randomized Trial Supply Management) for drug developers
and the global clinical research community. Calyx's market-leading
service, scientific knowledge, expertise, and technology offering
help speed up the delivery of life-saving treatments to millions of
patients around the world by accelerating and improving clinical
trial outcomes.
With operations in six countries, the company provides 24/7
services to most of the world's leading pharma and biotech
companies.
For more information go to Calyx.ai and follow us on LinkedIn,
Twitter, and Facebook.
Photo -
https://mma.prnewswire.com/media/2404560/Calyx_CEO_David_Herron.jpg
Logo - https://mma.prnewswire.com/media/1396338/Calyx_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/calyx-medical-imaging-supports-groundbreaking-melanoma-treatment-approval-302135974.html